[go: up one dir, main page]

YU27199A - Ziprasidon formulacije - Google Patents

Ziprasidon formulacije

Info

Publication number
YU27199A
YU27199A YU27199A YU27199A YU27199A YU 27199 A YU27199 A YU 27199A YU 27199 A YU27199 A YU 27199A YU 27199 A YU27199 A YU 27199A YU 27199 A YU27199 A YU 27199A
Authority
YU
Yugoslavia
Prior art keywords
ziprasidone
formulations
basis
ziprasidone formulations
schisophrenia
Prior art date
Application number
YU27199A
Other languages
English (en)
Inventor
Frank Robert Busch
Angela Carol Gatlin Hausberger
Bijan Rasadi
Daniel Ray Arenson
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22216447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU27199(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of YU27199A publication Critical patent/YU27199A/sh
Publication of RS49611B publication Critical patent/RS49611B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polyamides (AREA)
  • Detergent Compositions (AREA)
  • Feeding Of Articles By Means Other Than Belts Or Rollers (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Sastavi koji sadrže kristalnu slobodnu bazu ziprasidona ili kristalne čestice ziprasidon hidrohlorida koje imaju srednju veličinu manju od 85 Вµm i farmaceutski prihvatljiv nosilac i koji su u osnovi bioekvivalentni i mogu da budu korišćeni za tretiranje psihoza kao što je šizofrenija.[Compositions containing crystal free basis of ziprasidone or crystal particles of ziprasidone hydrochlorides that has medium size less than 85 Вµm and pharmaceutically acceptable basis and that represent bioequivalents and can be used for treating psychoses such as schisophrenia.
YUP-271/99A 1998-06-15 1999-06-14 Ziprasidon formulacije RS49611B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8922998P 1998-06-15 1998-06-15

Publications (2)

Publication Number Publication Date
YU27199A true YU27199A (sh) 2002-12-10
RS49611B RS49611B (sr) 2007-06-04

Family

ID=22216447

Country Status (44)

Country Link
US (1) US6150366A (sh)
EP (1) EP0965343B1 (sh)
JP (2) JP3441676B2 (sh)
KR (1) KR100338915B1 (sh)
CN (1) CN1307994C (sh)
AP (1) AP1216A (sh)
AR (1) AR015553A1 (sh)
AT (1) ATE240732T1 (sh)
AU (1) AU753820B2 (sh)
BG (1) BG64691B1 (sh)
BR (1) BR9902268A (sh)
CA (1) CA2274338C (sh)
CO (1) CO5070579A1 (sh)
CY (1) CY2003002I1 (sh)
CZ (1) CZ297954B6 (sh)
DE (1) DE69908021T2 (sh)
DK (1) DK0965343T3 (sh)
EA (1) EA002223B1 (sh)
ES (1) ES2197581T3 (sh)
GT (1) GT199900080A (sh)
HN (1) HN1999000089A (sh)
HR (1) HRP990193B1 (sh)
HU (1) HU226487B1 (sh)
ID (1) ID23546A (sh)
IL (1) IL130424A (sh)
IS (1) IS2182B (sh)
MA (1) MA26647A1 (sh)
MY (1) MY121397A (sh)
NO (1) NO316713B1 (sh)
NZ (1) NZ336271A (sh)
OA (1) OA11064A (sh)
PA (1) PA8475601A1 (sh)
PE (1) PE20000632A1 (sh)
PL (2) PL195606B1 (sh)
PT (1) PT965343E (sh)
RS (1) RS49611B (sh)
SG (1) SG77243A1 (sh)
SI (1) SI0965343T1 (sh)
SK (1) SK286245B6 (sh)
TR (1) TR199901379A2 (sh)
TW (1) TW590774B (sh)
UA (1) UA59383C2 (sh)
UY (1) UY25649A1 (sh)
ZA (1) ZA993938B (sh)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US7175855B1 (en) * 1999-05-27 2007-02-13 Pfizer Inc. Ziprasidone suspension
KR100477782B1 (ko) * 1999-05-27 2005-03-21 화이자 프로덕츠 인코포레이티드 지프라시돈 현탁액
EP2295043A1 (en) 1999-10-29 2011-03-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
EP2932964A1 (en) 2000-10-30 2015-10-21 Euro-Celtique S.A. Controlled release hydrocodone formulations
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
UY27668A1 (es) * 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
WO2003097046A1 (en) * 2002-05-17 2003-11-27 Duke University Method for treating obesity
US7488729B2 (en) * 2002-12-04 2009-02-10 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride salt and process for preparation thereof
WO2004050655A1 (en) * 2002-12-04 2004-06-17 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride
WO2004089948A1 (en) * 2003-04-11 2004-10-21 Hetero Drugs Limited Novel crystalline forms of ziprasidone hydrochloride
DE602004012403T2 (de) * 2003-04-29 2009-03-19 Orexigen Therapeutics, Inc., La Jolla Zusammensetzungen zur beeinflussung des gewichtsverlusts
WO2005016325A2 (en) * 2003-06-03 2005-02-24 Teva Pharmaceutical Industries Ltd. CRISTALLINE ZIPRASIDONE HCl AND PROCESSES FOR PREPARATION THEREOF
US20050049295A1 (en) * 2003-06-12 2005-03-03 Dr. Reddy's Laboratories Limited Process for the preparation of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1piperazinyl) ethyl)-6-chloro-1, 3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride) and its intermediate
CN1874761A (zh) * 2003-09-02 2006-12-06 辉瑞产品公司 齐拉西酮的持续释放剂型
WO2005040160A2 (en) * 2003-10-24 2005-05-06 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
EP1687300A4 (en) * 2003-11-28 2007-08-01 Wockhardt Ltd PROCESS FOR THE PREPARATION OF ZIPRASIDONE MONOHYDROCHLORIDE HYDRATE
WO2005061493A2 (en) 2003-12-18 2005-07-07 Teva Pharmaceutical Industries Ltd. Polymorphic form b2 of ziprasidone base
US20050163858A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Ziprasidone formulations
BRPI0506829A (pt) * 2004-01-13 2007-05-29 Univ Duke composições de anticonvulsivo e droga antipsicótica e métodos para sua utilização para afetar perda de peso
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
WO2005085240A2 (en) * 2004-02-27 2005-09-15 Ranbaxy Laboratories Limited Process for the preparation of ziprasidone
US20050277579A1 (en) * 2004-05-03 2005-12-15 Ranga Krishnan Compositions for affecting weight loss
WO2005107719A2 (en) * 2004-05-06 2005-11-17 Sandoz Ag Pharmaceutical composition comprising hydrophobic drug having improved solubility
CA2467538C (en) * 2004-05-14 2010-08-24 Apotex Pharmachem Inc. New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
WO2005123086A2 (en) * 2004-06-11 2005-12-29 Dr. Reddy's Laboratories Ltd. Ziprasidone dosage form
CA2471219A1 (en) * 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
WO2006026426A2 (en) * 2004-08-27 2006-03-09 University Of Kentucky Research Foundation Amyloid peptide inactivating enzyme to treat alzheimer’s disease peripherally
US20090142404A1 (en) 2004-08-31 2009-06-04 Pfizer Inc Pharmaceutical dosage forms comprising a low-solubility drug and a polymer
EA200701065A1 (ru) * 2004-11-16 2007-12-28 Элан Фарма Интернэшнл Лтд. Инъецируемые составы, содержащие нанодисперсный оланзапин
US20080268034A1 (en) * 2005-01-07 2008-10-30 Girish Karanth Solid Oral Dosage Forms of Ziprasidone Containing Colloidal Silicone Dioxide
US7749529B2 (en) * 2005-02-08 2010-07-06 Ash Access Technology, Inc. Catheter lock solution comprising citrate and a paraben
US20070032511A1 (en) * 2005-02-11 2007-02-08 Judith Aronhime Amorphous ziprasidone mesylate
ITMI20050346A1 (it) 2005-03-07 2006-09-08 Dipharma Spa Forma solida di ziprasidone cloridrato
CA2500667C (en) * 2005-03-11 2013-01-15 Apotex Pharmachem Inc. Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions
EP1858892A1 (en) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd Anhydrous ziprasidone mesylate and a process for its preparation
US20060270684A1 (en) * 2005-03-14 2006-11-30 Judith Aronhime Crystalline forms of ziprasidone mesylate
US20080305161A1 (en) * 2005-04-13 2008-12-11 Pfizer Inc Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
RU2407529C2 (ru) * 2005-04-13 2010-12-27 Пфайзер Продактс Инк. Инъецируемые препаративные формы депо и способы обеспечения замедленного высвобождения композиций, состоящих из наночастиц
JP2008538582A (ja) * 2005-04-22 2008-10-30 ワイス 精神病性障害の治療または予防のための新規の治療的組み合わせ
SI1884242T1 (sl) 2005-05-26 2013-07-31 Dainippon Sumitomo Pharma Co., Ltd. Farmacevtski sestavek, ki vsebuje lurazidon
KR20080024206A (ko) * 2005-06-20 2008-03-17 엘란 파마 인터내셔널 리미티드 아릴-헤테로시클릭 화합물을 함유하는 나노입자형 조절방출 조성물
JP2008546781A (ja) * 2005-06-20 2008-12-25 エラン・ファルマ・インターナショナル・リミテッド アリール−複素環式化合物を含んでなるナノ粒状及び制御放出の組成物
PL2135603T3 (pl) 2005-11-22 2013-09-30 Orexigen Therapeutics Inc Kompozycje i sposoby zwiększania wrażliwości na insulinę
AR057946A1 (es) * 2005-11-28 2007-12-26 Orexigen Therapeutics Inc Formulacion de zonisamida de liberacion sostenidda
PL379569A1 (pl) * 2006-04-28 2007-10-29 Pliva Kraków Zakłady Farmaceutyczne Spółka Akcyjna Sposób wytwarzania kompozycji farmaceutycznej zawierającej substancję aktywną ziprasidone lub jego farmaceutycznie dopuszczalną sól zwiększający rozpuszczalność i biodostępność tego leku, kompozycja farmaceutyczna i zastosowanie hydrofilowych substancji pomocniczych
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
EP1892243A1 (en) * 2006-08-02 2008-02-27 KRKA, tovarna zdravil, d.d., Novo mesto Polymorphic forms of ziprasidone sulphate salts
EP1889844A3 (en) * 2006-08-02 2008-03-05 Krka Polymorphic forms of ziprasidone sulphates
TW200829235A (en) 2006-11-09 2008-07-16 Orexigen Therapeutics Inc Methods for administering weight loss medications
EP2089005B1 (en) 2006-11-09 2010-03-17 Orexigen Therapeutics, Inc. Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer
AU2008254957A1 (en) * 2007-05-18 2008-11-27 Scidose Llc Ziprasidone formulations
WO2009032558A2 (en) * 2007-08-31 2009-03-12 Dr. Reddy's Laboratories Ltd. Preparation of ziprasidone hydrochloride monohydrate
US8410268B2 (en) * 2008-03-11 2013-04-02 Alkem Laboratories Limited Process for the preparation of ziprasidone
US20110144145A1 (en) 2008-05-30 2011-06-16 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
DE102008045854A1 (de) 2008-09-05 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Partikel aus Ziprasidone und einem Sprengmittel enthaltende Pharmazeutische Zusammensetzung
NZ597108A (en) 2009-06-25 2014-04-30 Alkermes Pharma Ireland Ltd Prodrugs of nh-acidic compounds
EP2340834A1 (en) 2009-12-30 2011-07-06 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Enhanced Solubility of Ziprasidone
JP6196041B2 (ja) 2010-01-11 2017-09-13 オレキシジェン・セラピューティクス・インコーポレーテッド 大うつ病を有する患者において減量療法を提供する方法
PL3251660T3 (pl) 2010-02-25 2020-02-28 Bristol-Myers Squibb Holdings Ireland Unlimited Company Formulacje apiksabanu
US20130108701A1 (en) 2010-05-25 2013-05-02 Krishna Murthy Bhavanasi Solid Dosage Forms of Antipsychotics
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
CA2875056C (en) 2012-06-06 2024-03-26 Orexigen Therapeutics, Inc. Methods of treating overweight and obesity
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA
US11273158B2 (en) 2018-03-05 2022-03-15 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264446A (en) * 1980-09-09 1993-11-23 Bayer Aktiengesellschaft Solid medicament formulations containing nifedipine, and processes for their preparation
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4883795A (en) * 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
DE4141268A1 (de) * 1991-12-14 1993-06-17 Merck Patent Gmbh Pharmazeutische zubereitung
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5338846A (en) * 1992-08-26 1994-08-16 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5359068A (en) * 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
PT790236E (pt) * 1996-02-13 2004-04-30 Pfizer Pro-farmacos de 5-(2-(4-(1,2-benzisotiazol-3-il)-1-piperazinil)-etil-6-cloro-1,3-di-hidro-2h-indol-2-ona
ATE364374T1 (de) * 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit

Also Published As

Publication number Publication date
CA2274338C (en) 2003-04-15
AP1216A (en) 2003-10-19
DE69908021D1 (de) 2003-06-26
PL195209B1 (pl) 2007-08-31
GT199900080A (es) 2000-11-29
MY121397A (en) 2006-01-28
EA199900467A3 (ru) 2000-04-24
EA002223B1 (ru) 2002-02-28
DE69908021T2 (de) 2003-11-27
IS5079A (is) 1999-12-16
IL130424A (en) 2003-10-31
HU226487B1 (en) 2009-03-02
UA59383C2 (uk) 2003-09-15
SK76999A3 (en) 2000-12-11
AP9901579A0 (en) 1999-06-30
CZ212799A3 (cs) 2000-09-13
CO5070579A1 (es) 2001-08-28
PL333737A1 (en) 1999-12-20
NO992892L (no) 1999-12-16
CA2274338A1 (en) 1999-12-15
BG64691B1 (bg) 2005-12-30
HU9901960D0 (en) 1999-08-30
EP0965343B1 (en) 2003-05-21
KR100338915B1 (ko) 2002-05-30
AR015553A1 (es) 2001-05-02
IL130424A0 (en) 2000-06-01
JP2000007566A (ja) 2000-01-11
HN1999000089A (es) 1999-11-03
EP0965343A3 (en) 2000-02-23
TW590774B (en) 2004-06-11
HRP990193B1 (en) 2003-08-31
ID23546A (id) 2000-05-04
CN1307994C (zh) 2007-04-04
BR9902268A (pt) 2000-05-02
SK286245B6 (sk) 2008-06-06
DK0965343T3 (da) 2003-08-04
NZ336271A (en) 2000-10-27
PL195606B1 (pl) 2007-10-31
ATE240732T1 (de) 2003-06-15
ES2197581T3 (es) 2004-01-01
PA8475601A1 (es) 2000-09-29
PE20000632A1 (es) 2000-07-26
NO316713B1 (no) 2004-04-13
UY25649A1 (es) 2000-02-23
BG103489A (en) 2000-07-31
IS2182B (is) 2006-12-15
HUP9901960A2 (hu) 2000-08-28
AU3398399A (en) 1999-12-23
OA11064A (en) 2002-03-13
CN1242987A (zh) 2000-02-02
RS49611B (sr) 2007-06-04
CZ297954B6 (cs) 2007-05-09
HK1024184A1 (en) 2000-10-05
JP2002003492A (ja) 2002-01-09
MA26647A1 (fr) 2004-12-20
US6150366A (en) 2000-11-21
AU753820B2 (en) 2002-10-31
JP3441676B2 (ja) 2003-09-02
SI0965343T1 (en) 2003-10-31
NO992892D0 (no) 1999-06-14
TR199901379A2 (xx) 2000-01-21
HRP990193A2 (en) 2000-02-29
CY2003002I1 (el) 2009-11-04
EA199900467A2 (ru) 1999-12-29
ZA993938B (en) 2000-12-14
PT965343E (pt) 2003-08-29
EP0965343A2 (en) 1999-12-22
JP4187423B2 (ja) 2008-11-26
KR20000006143A (ko) 2000-01-25
SG77243A1 (en) 2000-12-19
HUP9901960A3 (en) 2000-09-28

Similar Documents

Publication Publication Date Title
YU27199A (sh) Ziprasidon formulacije
AU3115395A (en) Dihydrobenzofuranes
ZA989875B (en) Composition and method for inhibiting the growth of microorganisms including stabilized sodium hypbromite and isothiazolones
HUT72081A (en) Pharmaceutical compositions containing the combination of a cholesterol biosynthesis inhibitor and a beta-lactam cholesterol absorption inhibitor and their production
HUP0101809A2 (hu) 5-és 3-as típusú 17béta-hidroxi-szteroid dehidrogenáz inhibitorok és ezeket tartalmazó gyógyászati készítmények
AU4205100A (en) Methods and compositions for the treatment of pancreatitis
NZ294421A (en) Dentifrice composition containing a precipitated silica having a mean particle size of 8-14 microns
IL114015A0 (en) Inhibitors of interleukin-1beta converting enzyme and pharmaceutical compositions containing the same
PL357002A1 (en) Composition for local application containing non-differentiated plant seed cells and method of using such composition
PL317195A1 (en) Application of agents in the form of gel as dressing compositions
AU3111395A (en) Triazole compounds and the use thereof
CY2476B1 (en) Benzonaphthyridines as bronchial therapeutics.
MXPA00012199A (es) Composicion de goma de gelano modificada, proceso para la preparacion de la misma y uso de esta.
PL340561A1 (en) Application of a combination of a converting enzyme inhibitor and a diuretic in treating microcirculatory disorders
GR3024667T3 (en) Cosmetical or pharmaceutical compositions comprising deacylated glycerophospholipids for topical use.
PL330148A1 (en) Non-peptidic mimetics of g-csf
DE59208300D1 (de) Verwendung von halogenkohlenwasserstoff-freien reinigungsmitteln zur fluxentfernung von elektronischen und elektrischen baugruppen
IL117209A0 (en) 1-aryl-2-acylamino-ethane compounds and pharmaceutical compositions containing them
AU3065999A (en) Compositions and methods for treatment of asthma
MY115533A (en) Benzothiophenes, formulation containing same and methods
MX9706958A (es) Composiciones refrigerantes.
AU2289495A (en) Dihydropyrimidine dehydrogenase compositions and methods of use
AU7961498A (en) 9a-azalides, compositions containing such compounds and methods of treatment
AU4660700A (en) Surface care compositions and methods for treating surfaces
AU2221400A (en) Compositions containing and methods of using n-acyl-1h-aminoindenes